We further evaluated the prognostic values of SFRPs in subdivided GC patients based on stages of cancer, Lauren classification, type of treatments, and human epidermal growth factor 2 (HER2) receptor status (Supplementary Figures S7–S10). Here, ERBB2 is linked to cancer.